Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: Pathophysiology and management

M. Packer, P. D. Kessler, S. S. Gottlieb

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

Although converting-enzyme inhibition is of established value in the management of patients with severe chronic congestive heart failure, troublesome adverse reactions occur frequently during the course of treatment and may cause physicians to interrupt effective therapy. The three most common adverse reactions that are seen in patients with heart failure following treatment with captopril and enalapril (symptomatic hypotension, functional renal insufficiency, hyperkalaemia) are predictable consequences of interfering with the homeostatic functions of the renin-angiotensin system, which evolved millions of years ago to preserve life in sodium-depleted states. It is not surprising, therefore, that these untoward effects can be prevented or reversed by increasing the dietary intake of salt or reducing the dose of concomitantly administered diuretics; their occurrence rarely requires discontinuation of drug therapy. Recognition of this link between sodium balance and the adverse effects of converting-enzyme inhibition is important, because most patients with severe heart failure who experience such untoward reactions can nevertheless be expected to improve clinically during long-term therapy, if effective treatment is not interrupted.

Original languageEnglish (US)
Pages (from-to)179-182
Number of pages4
JournalPostgraduate Medical Journal
Volume62
Issue numberSUPPL. 1
StatePublished - Jan 1 1986

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: Pathophysiology and management'. Together they form a unique fingerprint.

  • Cite this